* Harvard Bioscience Inc reported a quarterly adjusted loss of 2 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 1 cents. The mean expectation of three analysts for the quarter was for earnings of 3 cents per share. Wall Street expected results to range from zero cents to 5 cents per share.

* Revenue fell 13.4% to $21.97 million from a year ago; analysts expected $25.30 million.

* Harvard Bioscience Inc's reported EPS for the quarter was a loss of 11 cents​.

* The company reported a quarterly loss of $4.8 million.

* Harvard Bioscience Inc shares had risen by 4.8% this quarter and lost 47.3% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 46.7% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

Wall Street's median 12-month price target for Harvard Bioscience Inc is $6.25 This summary was machine generated from LSEG data November 7 at 08:44 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Jan. 1 0001 0.03 -0.02 Missed

Jun. 30 2024 0.05 0.00 Missed

Mar. 31 2024 0.02 0.02 Met

Dec. 31 2023 0.05 0.04 Missed